{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:29:04Z","timestamp":1782890944392,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clml.2020.05.021","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T19:01:27Z","timestamp":1591124487000},"page":"e694-e711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenstr\u00f6m Macroglobulinemia: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Ricardo D.","family":"Parrondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.05.021_bib1","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","article-title":"Waldenstr\u00f6m macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005","volume":"53","author":"Sekhar","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.05.021_bib2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.021_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2020.05.021_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.021_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16168","article-title":"Ibrutinib monotherapy outside of clinical trial setting in Waldenstr\u00f6m macroglobulinaemia: practice patterns, toxicities and outcomes","volume":"188","author":"Abeykoon","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.021_bib6","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1038\/bcj.2015.28","article-title":"Waldenstrom macroglobulinemia: prognosis and management","volume":"5","author":"Oza","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.05.021_bib7","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A\u00a0revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.021_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2010.029140","article-title":"Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia","volume":"96","author":"Hivert","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.05.021_bib9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstrom\u2019s macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.021_bib10","unstructured":"Kante SA, Majhail NS, Savani BN, et\u00a0al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy: guidelines for hematopoietic transplantation and cellular therapy. Biol Blood Marrow Transplant, in press."},{"key":"10.1016\/j.clml.2020.05.021_bib11","author":"Wells"},{"key":"10.1016\/j.clml.2020.05.021_bib12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3816\/CLM.2006.n.013","article-title":"Update on recommendations for assessing response from the Third International Workshop on Waldenstrom\u2019s macroglobulinemia","volume":"6","author":"Kimby","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2020.05.021_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clml.2020.05.021_bib14","series-title":"Advanced Theory of Statistics","author":"Stuart","year":"1994"},{"key":"10.1016\/j.clml.2020.05.021_bib15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2020.05.021_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.clml.2020.05.021_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2020.05.021_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2141.1999.01493.x","article-title":"Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia","volume":"106","author":"Dreger","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.021_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/sonc.2003.50048","article-title":"Transplantation in Waldenstrom\u2019s macroglobulinemia: the French experience","volume":"30","author":"Tournilhac","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2020.05.021_bib20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2006.04.010","article-title":"Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia","volume":"12","author":"Anagnostopoulos","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib21","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.021_bib22","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bmt.2014.113","article-title":"BEAM-conditioned autologous SCT improves the quality of response in Waldenstrom\u2019s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre\u2019s 10-year experience","volume":"49","author":"Marzolini","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib23","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00277-019-03734-7","article-title":"Outcomes of autologous stem cell transplantation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"98","author":"Saini","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.05.021_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3816\/CLML.2011.n.032","article-title":"Autologous stem cell transplantation as a care option in Waldenstrom\u2019s macroglobulinemia","volume":"11","author":"Usmani","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.05.021_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbmt.2007.01.083","article-title":"Autologous stem cell transplantation as part of first-line treatment of Waldenstrom\u2019s macroglobulinemia","volume":"13","author":"Dreger","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.bmt.1705748","article-title":"Evidence of graft-versus-Waldenstrom\u2019s macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience","volume":"40","author":"Stakiw","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3324\/haematol.2009.017814","article-title":"Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstr\u00f6m\u2019s macroglobulinemia. Results of a retrospective analysis of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"95","author":"Garnier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.05.021_bib28","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstr\u00f6m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.021_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2016.10.010","article-title":"Allogeneic Transplantation for relapsed Waldenstr\u00f6m macroglobulinemia and lymphoplasmacytic lymphoma","volume":"23","author":"Cornell","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib30","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.3324\/haematol.2017.184176","article-title":"Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstr\u00f6m macroglobulinemia: evidence for a graft-versus-lymphoma effect","volume":"103","author":"Maffini","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.05.021_bib31","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/bloodadvances.2017005637","article-title":"What should be the goal of therapy for Waldenstrom macroglobulinemia patients? Complete response should be the goal of therapy","volume":"1","author":"Treon","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.05.021_bib32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.021_bib33","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"iNNOVATE Study Group and the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.021_bib34","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bbmt.2015.05.010","article-title":"The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen","volume":"21","author":"Ispizua","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib35","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.021_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2019.12.766","article-title":"Outcomes of allogeneic stem cell transplant for elderly patients with hematologic malignancies","volume":"26","author":"Hsu","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib37","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.05.021_bib38","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.bbmt.2019.07.030","article-title":"Hematopoietic cell transplant\u2013related toxicities and mortality in frail recipients","volume":"25","author":"Pamukcuoglu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib39","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbmt.2019.12.724","article-title":"Respiratory viruses cause late morbidity in recipients of hematopoietic stem cell transplantation","volume":"26","author":"Marinelli","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib40","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/j.bbmt.2019.07.012","article-title":"Early prediction of cardiovascular risk after hematopoietic cell transplantation: are we there yet?","volume":"25","author":"Gavriilaki","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib41","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.bbmt.2019.06.035","article-title":"Integration of publicly reported center outcomes into standards and accreditation: the FACT model","volume":"25","author":"LeMaistre","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib42","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.bmt.1703190","article-title":"Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom\u2019s macroglobulinemia with severe pancytopenia","volume":"28","author":"Ueda","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib43","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.bmt.1701633","article-title":"Allogeneic bone marrow transplantation for advanced Waldenstrom\u2019s macroglobulinemia","volume":"23","author":"Martino","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1705702","article-title":"Long-term graft-versus-Waldenstrom macroglobulienmia effect following reduced intensity conditioning allogeneic stem cell transplantation","volume":"40","author":"Meniane","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib45","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.bbmt.2019.12.483","article-title":"Autologous stem cell transplant for Waldenstr\u00f6m macroglobulinemia in the era of novel therapies: still an underutilized tool?","volume":"26","author":"Parrondo","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2015.05.013","article-title":"Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the Surveillance, Epidemiology, and End Results-Medicare database","volume":"2","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JOP.2014.002469","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume":"11","author":"Shanafelt","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2020.05.021_bib48","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database","volume":"48","author":"Majhai","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib49","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbmt.2017.03.012","article-title":"In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study","volume":"23","author":"Sanchez","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.021_bib50","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term survival for myeloma after autologous stem cell transplantation","volume":"4","author":"Srour","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.05.021_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000360992","article-title":"Outcome disparities among ethnic subgroups of Waldenstrom's macroglobulinemia: a population-based study","volume":"86","author":"Ailawadhi","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2020.05.021_bib52","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41375-019-0592-8","article-title":"What is new in the treatment of Waldenstrom macroglobulienemia?","volume":"33","author":"Castillo","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.021_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2020.05.021_bib54","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.05.021_bib55","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.bbmt.2019.09.015","article-title":"Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on minimal residual disease and immune profiling","volume":"26","author":"Holstein","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:16Z","timestamp":1761870976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2152265020302676"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenstr\u00f6m Macroglobulinemia: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}